Lauren V Huckaby1, Laura M Seese2, Robert Handzel3, Yisi Wang2, Gavin Hickey4, Arman Kilic2. 1. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 2. Division of Cardiac Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 3. Department of Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 4. Division of Cardiology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.
Abstract
BACKGROUND: The use of hepatitis C virus-positive (HCV+) donors has expanded the donor pool for orthotopic heart transplantation (OHT). This study evaluated center-level trends and utilization of HCV+ donors for OHT. METHODS: Data were extracted from the Scientific Registry of Transplant Recipients on adults (≥18 y) undergoing OHT between January 1, 2016 and December 31, 2019. Centers performing <10 OHTs during the study period were excluded. Donor utilization rates were evaluated at the center level. Center-level characteristics were compared between centers performing HCV+ donor hepatitis C virus-negative (HCV-) recipient OHTs and those not utilizing HCV+ donors for HCV- recipients. RESULTS: A total of 10 134 patients underwent OHT, including 613 (6.05%) HCV+ donors transplanted into HCV- recipients. The number of HCV+ OHTs increased from 15 of 2512 (0.60%) in 2016 to 285 of 2490 (11.45%) in 2019 (P < 0.001). In 2016, among 105 centers performing OHTs, 7 (6.67%) utilized HCV+ donors compared to 2019 during which 55 (52.89%) of 104 centers utilized HCV+ donors (P < 0.001). In total, 57 of 107 (53.27%) centers utilized HCV+ donors during the study period. Centers utilizing HCV+ donors had higher overall donor utilization rates (7376/24 378 [30.26%] versus 3463/15 335 [22.58%], P < 0.001) and were higher volume as compared to nonutilizing centers (mean annual OHT volume 30.72 ± 1.21 versus 16.2 ± 1.40, P < 0.001). CONCLUSIONS: Although the use of HCV+ donors for OHT is rapidly expanding in the United States, almost half of transplant centers remain nonutilizers. Broader education and implementation of HCV+ donor protocols may be important in expanding OHT to more patients with end-stage heart failure.
BACKGROUND: The use of hepatitis C virus-positive (HCV+) donors has expanded the donor pool for orthotopic heart transplantation (OHT). This study evaluated center-level trends and utilization of HCV+ donors for OHT. METHODS: Data were extracted from the Scientific Registry of Transplant Recipients on adults (≥18 y) undergoing OHT between January 1, 2016 and December 31, 2019. Centers performing <10 OHTs during the study period were excluded. Donor utilization rates were evaluated at the center level. Center-level characteristics were compared between centers performing HCV+ donor hepatitis C virus-negative (HCV-) recipient OHTs and those not utilizing HCV+ donors for HCV- recipients. RESULTS: A total of 10 134 patients underwent OHT, including 613 (6.05%) HCV+ donors transplanted into HCV- recipients. The number of HCV+ OHTs increased from 15 of 2512 (0.60%) in 2016 to 285 of 2490 (11.45%) in 2019 (P < 0.001). In 2016, among 105 centers performing OHTs, 7 (6.67%) utilized HCV+ donors compared to 2019 during which 55 (52.89%) of 104 centers utilized HCV+ donors (P < 0.001). In total, 57 of 107 (53.27%) centers utilized HCV+ donors during the study period. Centers utilizing HCV+ donors had higher overall donor utilization rates (7376/24 378 [30.26%] versus 3463/15 335 [22.58%], P < 0.001) and were higher volume as compared to nonutilizing centers (mean annual OHT volume 30.72 ± 1.21 versus 16.2 ± 1.40, P < 0.001). CONCLUSIONS: Although the use of HCV+ donors for OHT is rapidly expanding in the United States, almost half of transplant centers remain nonutilizers. Broader education and implementation of HCV+ donor protocols may be important in expanding OHT to more patients with end-stage heart failure.
Authors: Leanne B Gasink; Emily A Blumberg; A Russell Localio; Shashank S Desai; Ajay K Israni; Ebbing Lautenbach Journal: JAMA Date: 2006-10-18 Impact factor: 56.272
Authors: Kelly H Schlendorf; Sandip Zalawadiya; Ashish S Shah; Mark Wigger; Chan Y Chung; Sarah Smith; Matthew Danter; Chun W Choi; Mary E Keebler; D Marshall Brinkley; Suzanne Brown Sacks; Henry Ooi; Roman Perri; Joseph A Awad; Samuel Lewis; Rachel Hayes; Heather O'Dell; Callie Darragh; Alicia Carver; Cori Edmonds; Shelley Ruzevich-Scholl; JoAnn Lindenfeld Journal: J Heart Lung Transplant Date: 2018-01-31 Impact factor: 10.247
Authors: J Levitsky; R N Formica; R D Bloom; M Charlton; M Curry; J Friedewald; J Friedman; D Goldberg; S Hall; M Ison; T Kaiser; D Klassen; G Klintmalm; J Kobashigawa; A Liapakis; K O'Conner; P Reese; D Stewart; N Terrault; N Theodoropoulos; J Trotter; E Verna; M Volk Journal: Am J Transplant Date: 2017-07-01 Impact factor: 8.086
Authors: Mary G Bowring; Ashton A Shaffer; Allan B Massie; Andrew Cameron; Niraj Desai; Mark Sulkowski; Jacqueline Garonzik-Wang; Dorry L Segev Journal: Am J Transplant Date: 2019-04-09 Impact factor: 8.086